Company Search:
Advanced Search
Sponsored Links
Xenetic Biosciences Inc Company Snapshot
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on progressing XCART, a personalized chimeric antigen receptor (CAR) T platform technology engineered to target patient-specific tumor neoantigens. The Company is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The Company is leveraging PolyXen, its drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen enables biological drugs by modifying their half-life and other pharmacological properties.

Sales Analysis.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Xenetic Biosciences Inc
  Stock Performance Chart for Xenetic Biosciences Inc
  Stock Data: Recent Stock Performance:
  Current Price (11/20/2020): .88
(Figures in U.S. Dollars)
1 Week 3.0%   13 Weeks -1.8%  
4 Weeks -22.8%   52 Weeks -17.8%  
Xenetic Biosciences Inc Key Data:
  Ticker: XBIO Country: United States
  Exchanges: OTC Major Industry: Transportation
    Sub Industry: Air Transportation
  2019 Sales 17,066
(Year Ending Jan 2020).
Employees: 4
  Currency: U.S. Dollars Market Cap: 5,540,680
  Fiscal Yr Ends: December Shares Outstanding: 6,296,227
  Share Type: Common Closely Held Shares: 925,085
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.